Antagonizing Dabigatran by Idarucizumab in Cases of Ischemic Stroke or Intracranial Hemorrhage in Germany – Updated Series of 120 Cases: Pawel Kermer
Listen now
Description
Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Patients with acute ischemic stroke on dabigatran treatment may become eligible for thrombolysis with rt-PA. In patients on dabigatran with intracerebral hemorrhage idarucizumab could prevent lesion growth. Carmen Lahiff-Jenkins, Managing Editor of the International Journal of Stroke spoke to Dr Pawel Kermer from Krankenhaus Sanderbusch; Neurology, Sande Germany.
Read the article link here
More Episodes
Stroke and COVID with Dr James Seigler
Published 09/07/20
Mobile stroke units, otherwise known as MSUs have recently been introduced in the care of patients suspected of having an acute stroke, leading to shortening in the time to thrombolytics, but how does the clinical effectiveness in terms of functional outcome and survival among patients treated in...
Published 08/19/20
Clinical assessment scores in acute ischemic stroke are only moderately correlated with lesion volume since lesion location is an important confounding factor. Many studies have investigated grey matter indicators of stroke severity but the understanding of white matter tract involvement is...
Published 07/21/20
Links
Twitter
Facebook
Instagram
Patreon
Genres
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
